Coeptis Therapeutics Q2 2023 Earnings Report

Coeptis Therapeutics EPS Results

• Actual EPS: -$2.80
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Coeptis Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Coeptis Therapeutics Announcement Details

• Quarter: Q2 2023
• Date: 8/28/2023
• Time: N/A

Coeptis Therapeutics (NASDAQ:COEP), a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.